China Launches 2026 National Medical Device Quality Sampling Inspection Program
China's National Medical Products Administration (NMPA) has officially launched its 2026 National Medical Device Quality Sampling Inspection Program, issuing a directive to provincial drug regulatory authorities and designated testing institutions across the country. The program covers 74 device categories spanning implantables, diagnostics, therapeutic equipment, and surgical consumables.
Program Overview
Under the directive, provincial and national testing institutions are required to conduct quality inspections in accordance with mandatory standards, registration requirements, and approved product technical specifications. Manufacturers found non-compliant after receiving inspection reports must immediately implement risk control measures, and cases involving potential criminal liability will be referred to judicial authorities. A re-inspection mechanism is also in place, allowing registrants or importers to apply once for re-testing at a designated institution, which is obligated to accept the request.
Key Device Categories Under Inspection
The 74 inspected categories span a broad spectrum of medical specialties. In the cardiovascular and vascular space, the program targets coronary and peripheral vascular stents, drug-coated balloon dilation catheters, embolic protection devices, and introducer sheaths. Orthopedic implants under review include hip and knee joint prostheses, a full range of spinal implants such as rods, screws, bone cement, and interbody fusion cages, as well as bone reconstruction materials, soft tissue repair implants, and artificial ligaments.
In ophthalmology, intraocular lenses, orthokeratology lenses, ophthalmic viscoelastics, and fundus cameras are among the products targeted. The audiology category — anchored by the newly added cochlear implant — also covers audiometers and box-type hearing aids.
The in vitro diagnostics segment includes detection kits for hepatitis C virus, influenza A/B antigens, Epstein-Barr virus nucleic acids, follicle-stimulating hormone, total bilirubin, and HBV pre-S2 antigens. On the therapeutic equipment side, the program covers ventilators and CPAP devices, high-frequency surgical equipment, Nd:YAG laser therapy machines, electronic analgesic pumps, and joint rehabilitation training devices.
Wound care and surgical consumables under inspection include barbed and chlorhexidine-coated absorbable sutures, emergency hemostatic bandages, polyurethane foam and hyaluronic acid sodium dressings, and disposable arterial compression devices. Dental ceramic materials and implants round out the consumables category. Other high-value devices targeted include color ultrasound systems, hemodialysis equipment, mobile X-ray machines, single-use electronic endoscopes, peritoneal dialysis catheters, and assisted reproduction culture dishes.
Deadlines and Compliance
Investigation results must be entered into the National Medical Device Sampling Information System within 30 working days of issuing a deficiency notice. Stakeholders with comments on related technical guidelines are asked to submit feedback by April 27, 2026.
Significance
This year's program signals China's sharpened regulatory focus on implantable and high-risk devices, particularly cochlear implants and orthopedic and cardiovascular implants — categories that directly impact patient safety and quality of life. The first-time inclusion of cochlear implants underscores the NMPA's commitment to closing regulatory gaps in advanced hearing restoration technology and signals heightened scrutiny for both domestic manufacturers and international players active in China's medical device market.